← Leaderboards
Daniel James Rader
University Of Pennsylvania
$77,348,993
Attributed
$101,293,085
Total exposure
56
Grants
29
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.3M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$101,293,085 · 56
By mechanism
R01$35,932,074 · 14
RC2$12,667,526 · 2
P01$11,975,773 · 7
U01$11,157,567 · 3
UM1$8,753,449 · 1
K12$4,065,101 · 1
Top collaborators
- Danish Saleheen21 shared
- John Navid Danesh9 shared
- Joseph A. Baur5 shared
- Rinad Sary Beidas5 shared
- Struan F A Grant5 shared
- Klaus H. Kaestner5 shared
- Patrick Seale5 shared
- Kathleen E Sullivan5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Rinad Sary Beidas$17,490,789
- Kevin G Volpp$33,636,384
- James M Wilson$22,532,723
- Kiran Musunuru$21,648,838
- Raquel E Gur$68,119,194
Others in their field
Top investigators on “Atherosclerosis”
- Eric A Boerwinkle · University Of Texas Hlth Sci Ctr Houston$63,519,256
- Josef Coresh · New York University School Of Medicine$60,445,875
- Howard N Hodis · University Of Southern California$49,943,399
- Gary K Owens · University Of Virginia$42,472,259
- Alan Richard Tall · Columbia University Health Sciences$38,866,887
- Peter O Kohler · Oregon Health And Science University$38,512,009
Research focus
AtherosclerosisPlasmaGenesHigh Density LipoproteinsLipidsLipoproteinsVariantProteinsBaseClinical ResearchPhenotypeMetabolismPathway InteractionsGenome Wide Association StudyMolecularGenotypeMediatingCholesterolBiologicalHuman SubjectGeneticTriglyceridesRegulationCells
Grant awards (200)
Mechanisms by which ABCA7 activity influences Alzheimer's Disease$1,256,699
RF1 · FY2025 · AG · contact PI
From genetic association to function: pleiotropic novel genes and variants linking lipid metabolism and cardiovascular diseases$1,111,752
R35 · FY2025 · HL · contact PI
Leveraging behavioral economics to equitably implement cascade screening in individuals with familial hypercholesterolemia in partnership with the FH Foundation$555,134
R33 · FY2025 · HL
Functional Interrogation of T2D-associated genes in human stem cell-derived models and mice$1,635,817
UM1 · FY2024 · DK
From genetic association to function: pleiotropic novel genes and variants linking lipid metabolism and cardiovascular diseases$1,123,889
R35 · FY2024 · HL · contact PI
Leveraging behavioral economics to equitably implement cascade screening in individuals with familial hypercholesterolemia in partnership with the FH Foundation$550,457
R33 · FY2024 · HL
Leveraging behavioral economics to equitably implement cascade screening in individuals with familial hypercholesterolemia in partnership with the FH Foundation$64,217
R33 · FY2024 · HL
Functional Interrogation of T2D-associated genes in human stem cell-derived models and mice$1,741,729
UM1 · FY2023 · DK
Structure-Function Analysis of Triglyceride Regulator ApoA-V Using Natural Variants$789,784
R01 · FY2023 · HL · contact PI
Leveraging behavioral economics to equitably implement cascade screening in individuals with familial hypercholesterolemia in partnership with the FH Foundation$640,144
R33 · FY2023 · HL
UDN@CHOP/UPENN: transition to sustainability$618,882
U01 · FY2023 · NS
UDN@CHOP/UPENN: transition to sustainability$356,000
U01 · FY2023 · NS
Mechanisms by which ABCA7 activity influences Alzheimer's Disease$2,121,130
RF1 · FY2022 · AG · contact PI
Functional Interrogation of T2D-associated genes in human stem cell-derived models and mice$1,777,640
UM1 · FY2022 · DK
Structure-Function Analysis of Triglyceride Regulator ApoA-V Using Natural Variants$753,964
R01 · FY2022 · HL · contact PI
Undiagnosed diseases network clinical site$644,376
U01 · FY2022 · HG
Deep phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 human knockouts and population based studies$619,439
R01 · FY2022 · HL
Leveraging behavioral economics to equitably implement cascade screening in individuals with familial hypercholesterolemia in partnership with the FH Foundation$392,205
R61 · FY2022 · HL
Functional Interrogation of T2D-associated genes in human stem cell-derived models and mice$1,843,580
UM1 · FY2021 · DK
Structure-Function Analysis of Triglyceride Regulator ApoA-V Using Natural Variants$745,884
R01 · FY2021 · HL · contact PI
Deep Phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 Human Knockouts and Population Based Studies$700,193
R01 · FY2021 · HL · contact PI
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis$541,108
R01 · FY2021 · DK · contact PI
Mechanisms underlying the genetic association between PPP1R3B and Alzheimer's Disease$406,248
R01 · FY2021 · DK · contact PI
Undiagnosed diseases network clinical site$350,000
U01 · FY2021 · HG
Functional Interrogation of T2D-associated genes in human stem cell-derived models and mice$1,754,683
UM1 · FY2020 · DK
Deep Phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 Human Knockouts and Population Based Studies$722,788
R01 · FY2020 · HL · contact PI
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis$691,510
R01 · FY2020 · DK · contact PI
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway$678,976
R01 · FY2020 · HL · contact PI
Undiagnosed diseases network clinical site$550,000
U01 · FY2020 · HG
Trib1 regulation of hepatic lipid metabolism and atherogenesis$402,500
R01 · FY2020 · HL · contact PI
Deep Phenotyping of ANGPTL3, ANGPTL4 and ANGPTL8 Human Knockouts and Population Based Studies$760,417
R01 · FY2019 · HL
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway$692,812
R01 · FY2019 · HL · contact PI
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis$646,698
R01 · FY2019 · DK · contact PI
Project 2 Optimizing Liver-Directed Gene Therapy for Inherited Dyslipidemia$414,720
P01 · FY2019 · HL · contact PI
Trib1 regulation of hepatic lipid metabolism and atherogenesis$402,500
R01 · FY2019 · HL · contact PI
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants$396,026
R01 · FY2019 · HL · contact PI
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway$699,514
R01 · FY2018 · HL
Molecular mechanisms linking the CXCL12 pathway to atherosclerosis$687,311
R01 · FY2018 · HL · contact PI
Molecular mechanisms underlying the genetic association between PPP1R3B and hepatic steatosis$630,762
R01 · FY2018 · DK · contact PI
Project 2 Optimizing Liver-Directed Gene Therapy for Inherited Dyslipidemia$418,810
P01 · FY2018 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$415,681
R37 · FY2018 · HL · contact PI
Trib1 regulation of hepatic lipid metabolism and atherogenesis$402,500
R01 · FY2018 · HL · contact PI
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants$396,026
R01 · FY2018 · HL · contact PI
Deep Phenotyping of Human Knockouts and Population Studies of the APOC3 Pathway$753,746
R01 · FY2017 · HL
Molecular mechanisms linking the CXCL12 pathway to atherosclerosis$704,966
R01 · FY2017 · HL
HDL metabolism: Influence of extracellular lipases$439,329
R37 · FY2017 · HL · contact PI
Project 2 Optimizing Liver-Directed Gene Therapy for Inherited Dyslipidemia$431,878
P01 · FY2017 · HL · contact PI
Trib1 regulation of hepatic lipid metabolism and atherogenesis$402,500
R01 · FY2017 · HL · contact PI
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants$396,026
R01 · FY2017 · HL · contact PI
Molecular mechanisms linking the CXCL12 pathway to atherosclerosis$733,396
R01 · FY2016 · HL
Discovery and Validation of Novel Loci Associated with HDL Function$665,837
R01 · FY2016 · HL · contact PI
Project 2 Optimizing Liver-Directed Gene Therapy for Inherited Dyslipidemia$428,779
P01 · FY2016 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$400,000
R37 · FY2016 · HL · contact PI
Structure-Function Analysis of Triglyceride Regulators ApoC-III and ApoA-V Using Natural Variants$396,026
R01 · FY2016 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$26,784
R37 · FY2016 · HL · contact PI
iPS-derived hepatocytes for interrogation of lipid phenotypes$2,175,201
U01 · FY2015 · HG · contact PI
Molecular mechanisms linking the CXCL12 pathway to atherosclerosis$791,469
R01 · FY2015 · HL
Discovery and Validation of Novel Loci Associated with HDL Function$662,851
R01 · FY2015 · HL · contact PI
Project 2 Optimizing Liver-Directed Gene Therapy for Inherited Dyslipidemia$420,800
P01 · FY2015 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$394,000
R37 · FY2015 · HL · contact PI
iPS-derived hepatocytes for interrogation of lipid phenotypes$2,201,553
U01 · FY2014 · HG · contact PI
Discovery and Validation of Novel Loci Associated with HDL Function$669,898
R01 · FY2014 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$400,000
R37 · FY2014 · HL · contact PI
Interrogation of novel pathways regulating VLDL production and plasma lipids$392,000
R01 · FY2014 · HL · contact PI
iPS-derived hepatocytes for interrogation of lipid phenotypes$2,177,607
U01 · FY2013 · HG · contact PI
Discovery and Validation of Novel Loci Associated with HDL Function$645,352
R01 · FY2013 · HL · contact PI
Genetics of lipoprotein metabolism and CVD in CKD$444,874
R01 · FY2013 · HL · contact PI
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial$400,059
R01 · FY2013 · HL · contact PI
Interrogation of novel pathways regulating VLDL production and plasma lipids$380,800
R01 · FY2013 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIAS$379,448
P01 · FY2013 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$371,102
R37 · FY2013 · HL · contact PI
MOLECULAR REGULATION OF HDL METABOLISM & REVERSE CHOLESTEROL TRANSPORT$322,980
P01 · FY2013 · HL · contact PI
iPS-derived hepatocytes for interrogation of lipid phenotypes$1,280,948
U01 · FY2012 · HG · contact PI
Genetics of Elevated High Density Lipoprotein Cholesterol$781,434
R01 · FY2012 · HL · contact PI
Discovery and Validation of Novel Loci Associated with HDL Function$675,261
R01 · FY2012 · HL · contact PI
Genetics of lipoprotein metabolism and CVD in CKD$512,094
R01 · FY2012 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIAS$433,952
P01 · FY2012 · HL · contact PI
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial$428,498
R01 · FY2012 · HL · contact PI
Interrogation of novel pathways regulating VLDL production and plasma lipids$400,000
R01 · FY2012 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$389,813
R37 · FY2012 · HL · contact PI
MOLECULAR REGULATION OF HDL METABOLISM & REVERSE CHOLESTEROL TRANSPORT$305,338
P01 · FY2012 · HL · contact PI
iPS-derived hepatocytes for interrogation of lipid phenotypes$803,000
U01 · FY2011 · HG · contact PI
Genetics of Elevated High Density Lipoprotein Cholesterol$781,429
R01 · FY2011 · HL · contact PI
Genetics of lipoprotein metabolism and CVD in CKD$503,898
R01 · FY2011 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIAS$441,095
P01 · FY2011 · HL · contact PI
Interrogation of novel pathways regulating VLDL production and plasma lipids$400,000
R01 · FY2011 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$393,750
R37 · FY2011 · HL · contact PI
MOLECULAR REGULATION OF HDL METABOLISM & REVERSE CHOLESTEROL TRANSPORT$350,331
P01 · FY2011 · HL · contact PI
Comprehensive biomarker study to capitalize on existing GWAS in 10K South Asians$4,199,069
RC2 · FY2010 · HL · contact PI
Molecular mechanisms and pathways of novel genomic loci regulating plasma lipids$2,300,000
RC2 · FY2010 · HL · contact PI
Genetics of Elevated High Density Lipoprotein Cholesterol$782,029
R01 · FY2010 · HL · contact PI
Genetics of lipoprotein metabolism and CVD in CKD$508,989
R01 · FY2010 · HL · contact PI
Identification of Causal Variants at Novel GWAS Loci Associated with Lipid Traits$500,000
RC1 · FY2010 · HL · contact PI
Markers of the metabolic syndrome linking type 2 diabetes and MI in South Asia$499,993
RC1 · FY2010 · TW · contact PI
GENE THERAPY FOR DYSLIPIDEMIAS$432,414
P01 · FY2010 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$393,750
R37 · FY2010 · HL · contact PI
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial$383,483
R01 · FY2010 · HL · contact PI
MOLECULAR REGULATION OF HDL METABOLISM & REVERSE CHOLESTEROL TRANSPORT$339,266
P01 · FY2010 · HL · contact PI
Comprehensive biomarker study to capitalize on existing GWAS in 10K South Asians$3,768,457
RC2 · FY2009 · HL · contact PI
Molecular mechanisms and pathways of novel genomic loci regulating plasma lipids$2,400,000
RC2 · FY2009 · HL · contact PI
Genetics of Elevated High Density Lipoprotein Cholesterol$795,258
R01 · FY2009 · HL · contact PI
Genetics of lipoprotein metabolism and CVD in CKD$510,376
R01 · FY2009 · HL · contact PI
Identification of Causal Variants at Novel GWAS Loci Associated with Lipid Traits$500,000
RC1 · FY2009 · HL · contact PI
Markers of the metabolic syndrome linking type 2 diabetes and MI in South Asia$499,993
RC1 · FY2009 · TW · contact PI
HDL metabolism: Influence of extracellular lipases$393,750
R37 · FY2009 · HL · contact PI
Molecular Regulation of HDL Metabolism and Reverse Cholesterol Transport$341,954
P01 · FY2009 · HL · contact PI
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial$311,988
R01 · FY2009 · HL · contact PI
HDL metabolism: Influence of extracellular lipases$41,731
R01 · FY2009 · HL · contact PI
Genetics of Elevated High Density Lipoprotein Cholesterol$809,661
R01 · FY2008 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS$440,451
P01 · FY2008 · HL · contact PI
ApoE and Regulation of COX-2 in VSMCs$429,732
P01 · FY2008 · HL · contact PI
High Density Lipoprotein Metabolism Influence of Extracellular Phospholipases$338,147
R01 · FY2008 · HL · contact PI
Effects of Niacin on Lp(a), Oxidized LDL, and inflammation in the AIM-HIGH trial$301,776
R01 · FY2008 · HL · contact PI
APO A-1 and Reverse Cholesterol Transport in Vivo$680,520
P01 · FY2007 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS$438,506
P01 · FY2007 · HL · contact PI
ApoE and Regulation of COX-2 in VSMCs$434,529
P01 · FY2007 · HL · contact PI
High Density Lipoprotein Metabolism Influence of Extracellular Phospholipases$338,147
R01 · FY2007 · HL · contact PI
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS$424,980
P01 · FY2006 · HL · contact PI
APO A-1 and Reverse Cholesterol Transport in Vivo$421,244
P01 · FY2006 · HL · contact PI
HDL Metabolism Influence of Extracellular Phospholipases$348,245
R01 · FY2006 · HL · contact PI
ApoE and Regulation of COX-2 in VSMCs$294,024
P01 · FY2006 · HL · contact PI
Antioxidant and Anti-inflammatory Mechanisms of HDL$258,389
P50 · FY2006 · HL · contact PI
Mentored Career Development in Patient Oriented Research$1
K12 · FY2006 · RR · contact PI
Mentored Career Development in Patient Oriented Research$1,235,490
K12 · FY2005 · RR
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS$414,718
P01 · FY2005 · HL
APO A-1 and Reverse Cholesterol Transport in Vivo$408,978
P01 · FY2005 · HL
HDL Metabolism Influence of Extracellular Phospholipases$356,625
R01 · FY2005 · HL
ApoE and Regulation of COX-2 in VSMCs$285,666
P01 · FY2005 · HL
Antioxidant and Anti-inflammatory Mechanisms of HDL$250,862
P50 · FY2005 · HL
HDL-CHOLESTEROL AND INFLAMMATION AND OXIDATIVE STRESS$133,961
M01 · FY2005 · RR
EFFECTS OF ROSIGLITAZONE ON HDL IN NON-DIABETIC PATIENTS WITH METABOLIC SYNDROME$77,718
M01 · FY2005 · RR
A MECHANISTIC STUDY OF THE EFFECTS OF ROSIGLITAZONE ON HDL METABOLISM$74,309
M01 · FY2005 · RR
ORALLY ADMINISTERED D-4F IN NORMAL HEALTHY VOLUNTEERS$40,904
M01 · FY2005 · RR
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$18,747
M01 · FY2005 · RR
MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) INHIBITOR BMS-201038$17,384
M01 · FY2005 · RR
HEFH IMPLITAPIDE STUDY$15,339
M01 · FY2005 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$13,634
M01 · FY2005 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS IN HIV SUBJECTS$12,665
M01 · FY2005 · RR
HTG IMPLITAPIDE STUDY$1,363
M01 · FY2005 · RR
HOFH IMPLITAPIDE STUDY$341
M01 · FY2005 · RR
Mentored Career Development in Patient Oriented Research$1,235,490
K12 · FY2004 · RR
GENE THERAPY FOR DYSLIPIDEMIA AND ATHEROSCLEROSIS$403,669
P01 · FY2004 · HL
APO A-1 and Reverse Cholesterol Transport in Vivo$397,065
P01 · FY2004 · HL
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$372,850
R01 · FY2004 · DK
HDL Metabolism Influence of Extracellular Phospholipases$356,625
R01 · FY2004 · HL
ApoE and Regulation of COX-2 in VSMCs$277,336
P01 · FY2004 · HL
Antioxidant and Anti-inflammatory Mechanisms of HDL$243,556
P50 · FY2004 · HL
HDL-Cholesterol and Inflammation and Oxidative Stress$128,192
M01 · FY2004 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$77,499
R01 · FY2004 · DK
BMS-201038 in Patients with Homozygous Familial Hypercholesterolemia$27,698
M01 · FY2004 · RR
Rosiglitazone on HDL in Non-Diabetic Patients with the Metabolic Syndrome$25,213
M01 · FY2004 · RR
Gordon Research Conference: Lipoprotein Metabolism 2004$14,000
R13 · FY2004 · HL
Abnormal Plasma Lipid Levels in Persons at Risk for Premature CHD$13,138
M01 · FY2004 · RR
Mechanism of PI-Related Dyslipidemia and Atherosclerosis$6,777
M01 · FY2004 · RR
A Mechanistic Study of the Effects of Rosiglitazone on HDL Metabolism$5,327
M01 · FY2004 · RR
Association of Coronary Calcification with Genetic Markers for Atherosclerosis$355
M01 · FY2004 · RR
Mentored Career Development in Patient Oriented Research$1,053,231
K12 · FY2003 · RR
APO A-1 and Reverse Cholesterol Transport in Vivo$385,501
P01 · FY2003 · HL
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$372,850
R01 · FY2003 · DK
HDL METABOLISM:INFLUENCE OF EXTRACELLULAR PHOSPHOLIPASES$317,000
R01 · FY2003 · HL
Antioxidant and Anti-inflammatory Mechanisms of HDL$236,463
P50 · FY2003 · HL
Mentored Career Development in Patient Oriented Research$540,889
K12 · FY2002 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$372,850
R01 · FY2002 · DK
HDL METABOLISM:INFLUENCE OF EXTRACELLULAR PHOSPHOLIPASES$317,000
R01 · FY2002 · HL
GENE THERAPY OF ATHEROSCLEROSIS$126,320
P01 · FY2002 · HL
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$124,146
M01 · FY2002 · RR
CHRONIC DOSING OF BMS-201038 AND HEPATIC FAT ACCUMULATION, AND REVERSIBILITY$124,146
M01 · FY2002 · RR
GENE THERAPY FOR FH: EVALUATION WITH LIPOPROTEIN KINETIC STUDIES$124,146
M01 · FY2002 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$124,146
M01 · FY2002 · RR
SOFT GEL CONTAINING PLANT STANOL ESTERS TO HELP REDUCE TOTAL AND LDL CHOLESTEROL$124,146
M01 · FY2002 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$75,414
R01 · FY2002 · DK
Antioxidant and antiinflammatory mechanisms of HDL$0
P50 · FY2002 · HL
EX VIVO GENE THERAPY FOR FAMILIAL HYPERCHOLESTEROLEMIA$0
M01 · FY2002 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$372,850
R01 · FY2001 · DK
CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E$347,847
R01 · FY2001 · HL
HDL METABOLISM:INFLUENCE OF EXTRACELLULAR PHOSPHOLIPASES$317,000
R01 · FY2001 · HL
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$124,146
M01 · FY2001 · RR
SOFT GEL CONTAINING PLANT STANOL ESTERS TO HELP REDUCE TOTAL AND LDL CHOLESTEROL$124,146
M01 · FY2001 · RR
CHRONIC DOSING OF BMS-201038 AND HEPATIC FAT ACCUMULATION, AND REVERSIBILITY$124,146
M01 · FY2001 · RR
GENE THERAPY FOR FH: EVALUATION WITH LIPOPROTEIN KINETIC STUDIES$124,146
M01 · FY2001 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$124,146
M01 · FY2001 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$73,400
R01 · FY2001 · DK
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$0
M01 · FY2001 · RR
CHRONIC DOSING OF BMS-201038 AND HEPATIC FAT ACCUMULATION, AND REVERSIBILITY$0
M01 · FY2001 · RR
GENE THERAPY FOR FH: EVALUATION WITH LIPOPROTEIN KINETIC STUDIES$0
M01 · FY2001 · RR
GENE THERAPY OF ATHEROSCLEROSIS$0
P01 · FY2001 · HL
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$0
M01 · FY2001 · RR
SOFT GEL CONTAINING PLANT STANOL ESTERS TO HELP REDUCE TOTAL AND LDL CHOLESTEROL$0
M01 · FY2001 · RR
MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS$387,475
R01 · FY2000 · DK
CELLULAR BASIS OF ANTIATHEROGENESIS BY APOLIPOPROTEIN E$338,585
R01 · FY2000 · HL
HDL METABOLISM:INFLUENCE OF EXTRACELLULAR PHOSPHOLIPASES$317,000
R01 · FY2000 · HL
GENE THERAPY OF ATHEROSCLEROSIS$250,769
P01 · FY2000 · HL
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$25,114
M01 · FY2000 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$25,114
M01 · FY2000 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$0
M01 · FY2000 · RR
SOFT GEL CONTAINING PLANT STANOL ESTERS TO HELP REDUCE TOTAL AND LDL CHOLESTEROL$0
M01 · FY2000 · RR
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$0
M01 · FY2000 · RR
ABNORMAL PLASMA LIPID LEVELS IN PERSONS AT RISK FOR PREMATURE CHD$0
M01 · FY2000 · RR
EX VIVO GENE THERAPY FOR FAMILIAL HYPERCHOLESTEROLEMIA$0
M01 · FY2000 · RR
ASSOCIATION OF CORONARY CALCIFICATION WITH GENETIC MARKERS FOR ATHEROSCLEROSIS$0
M01 · FY2000 · RR